Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease

References

• Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/international Gastroenterology Surveillance Study (DIGEST). Scan. J. Gasteroenterol.231(Suppl.), 29–37 (1999).
   PubMed Web of Science ®Google Scholar
• Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am. J. Gastroenterol.98(Suppl. 3), S8–S14 (2003).
   Google Scholar
• Maconi G, Tosetti C, Stanghellini V, Porro GB, Corinaldesi R. Dyspeptic symptoms in primary care. An observational study in general practice. Eur. J. Gastroenterol. Hepatol.14, 985–990 (2002).
   PubMed Web of Science ®Google Scholar
• Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am. J. Gastroenterol.98(Suppl. 3), S2–S7 (2003).
   PubMed Web of Science ®Google Scholar
• Rosaida MS, Goh KL. Gastro-esophageal reflux disease, reflux oesophagitis and non-erosive reflux disease in a multiracial Asian population: prospective, endoscopy based study. Eur. J. Gastroenterol. Hepatol.16, 495–501 (2004).
   PubMed Web of Science ®Google Scholar
• Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD) – acid reflux and symptom patterns. Aliment Pharmacol. Ther.17, 537–545 (2003).
   PubMed Web of Science ®Google Scholar
• Ronkainen JA, Aro PT, Storskrubb T et al. Prevalence of esophagitis and endoscopy-negative reflux disease in a population. A report from the Kalixandra study. Gastroenterology122(Suppl.), A213–(S1357) (2002).
   Web of Science ®Google Scholar
• Lind T, Havelund T, Carlsson R et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand. J. Gastroenterol.32, 974–979 (1977).
   Google Scholar
• Jones RH, Hungin AP, Phillips J et al. Gastro-esophageal reflux disease in primary care in Europe: clinical presentation and endoscopic findings. Eur. J. Gen. Pract.1, 149–154 (1995).
   Google Scholar
• Ministry of Health. Drug Utilisation in Italy, National Report 2003. (L’uso dei Farmaci in Italia. Rapporto nazionale anno 2003). Il Pensiero Scientifico Editore, Rome, Italy. (2004).
   Google Scholar
• Lucioni C, Mazzi S. Realtà prescrittive versus standard di consumo nel campo degli inibitori della pompa protonica in Italia. Pharmacoeconomics – Ital. Res. Articles5, 3–10 (2003).
   Google Scholar
• Pace F, Pallotta S, Bianchi Porro G. On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease. Dig. Liver Dis.34, 870–877 (2002).
   PubMedGoogle Scholar
• Talley NJ, Venables TL, Green JR et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur. J. Gastroenterol. Hepatol.14, 857–863 (2002).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol. Ther.15, 347–354 (2001).
   PubMed Web of Science ®Google Scholar
• Cooper AL, Baxter G. Efficacy of lansoprazole on demand therapy in the treatment of non-erosive reflux disease and functional ulcer-like dyspepsia. Gut52(Suppl. VI), A137 (2003).
   Google Scholar
• Scholten T, Dekkers CPM, Schutze K, Bohuschke M, Gatz G. On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. ALTANA Satellite Symposium at the 10th United European Gastroenterology Week, 20th October, Geneva, Switzerland (2002).
   Google Scholar
• Kaspari S, Kupcinskas L, Fischer R, Berghöfer P. On-demand therapy with pantoprazole 20mg as effective long-term management of patients suffering from mild GERD. Gastroenterology124(4 Suppl. 1), A538 (2003).
   Google Scholar
• Bytzer P, Blum A, De Herdt D, Dubois D, The Trial Investigators. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol. Ther.20, 181–188 (2004).
   PubMed Web of Science ®Google Scholar
• Lind T, Havelund T, Lundell L et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis – a placebo-controlled randomized trial. Aliment Pharmacol. Ther.13, 907–914 (1999).
   PubMed Web of Science ®Google Scholar
• Savary M, Miller G. The Esophagus: Handbook and Atlas of Endoscopy. Verlag Gassman, Solothurn, Switzerland, 135–142 (1978).
   Google Scholar
• Kartman B, Gatz G, Johannesson M. Health state utilities in GERD patients with heartburn: a study in Germany and Sweden. Med. Dec. Making23, 40–52 (2004).
   Google Scholar
• The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Pol.16, 199–208 (1990).
   PubMed Web of Science ®Google Scholar
• Kind P, Hardman G, Macran S. UK Population norms for EQ-5D. Discussion Paper 172. York Centre for Health Economics, York, UK (1999).
   Google Scholar
• Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Dec. Making23, 341–50 (2003).
   PubMed Web of Science ®Google Scholar
• Colombo GL, Caruggi M, Vinci M. Costo sociale annuo della dispepsia funzionale dopo l’eradicazione dell’Helicobacter pylori. Risultati di un’indagine in centri di endocscopia digestiva. Pharmacoeconomics Ital. Res. Articles (2005) (In Press).
   Google Scholar
• Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G. Il costo sociale del diabete di tipo 2 in Italia: lo studio CODE-2. Pharmacoeconomics Ital. Res. Articles2, 1–21 (2000).
   Google Scholar
• Haycox A, Einarson T, Eggleston A. The health economic impact of upper gastrointestinal symptoms in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand. J. Gastroenterol.231(Suppl.), 38–47 (1999).
   Google Scholar
• Stinnett M. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med. Dec. Making18(Suppl. 2), S68–S80 (1998).
   PubMed Web of Science ®Google Scholar
• Colombo G, Muzio A. Gli inibitori della pompa protonica nelle patologie acido-correlate: il ruolo di rabeprazolo in una strategia di cost-minimization. Farmacoeconomia e percorsi terapeutici4, 39–46 (2003).
   Google Scholar
• Ponce J, Arguello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig. Dis. Sci.49, 931–936 (2004).
   PubMed Web of Science ®Google Scholar
• Liu JY, Woloshin S, Laycock WS, Rothstein RI, Finlayson SR, Schwartz LM. Symptoms and treatment burden of gastroesophageal reflux disease: validating the GERD assessment scales. Arch. Intern. Med.164, 2058–2064 (2004).
   PubMedGoogle Scholar
• De La Loge C, Trudeau E, Marquis P et al. Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders. Clin. Gastroenterol. Hepatol.2, 778–786 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson DA. Endpoints for the assessment of response to gastroesophageal reflux disease therapy – what are the appropriate measures of “success”? Rev. Gastroenterol. Disord.4, 118–128 (2004).
   PubMedGoogle Scholar
• Irvine EJ. Quality of life assessment in gastro-oesophageal reflux disease. Gut53(Suppl. 4), 35–39 (2004).
   Web of Science ®Google Scholar
• Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut53(Suppl. 4), 1–24 (2004).
   PubMed Web of Science ®Google Scholar
• Goeree R, O’Brien B, Hunt R et al. Economic evaluation of long term management strategies for erosive oesophagitis. PharmacoEconomics16, 679–697 (1999).
   PubMed Web of Science ®Google Scholar
• Gerson LB, Robbins AS, Garber A et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am. J. Gastroenterol.95, 395–407 (2000).
   PubMed Web of Science ®Google Scholar
• Harris RA, Kuppermann M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am. J. Med.102, 78–88 (1997).
   PubMed Web of Science ®Google Scholar
• Inadomi JM. On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations. PharmacoEconomics20, 565–576 (2002).
   PubMed Web of Science ®Google Scholar
• Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. PharmacoEconomics20, 267–277 (2002).
   PubMed Web of Science ®Google Scholar
• Stalhammar N-O, Carlsson J, Peacock R et al. Cost-effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oeasophageal reflux disease. PharmacoEconomics16, 483–497 (1999).
   PubMed Web of Science ®Google Scholar
• Ministry of Health Decree 22nd July 1996. “Prestazioni di Assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio Sanitario nazionale e relative tariffe.” Gazzetta Ufficiale216(Suppl.), (1996).
   Google Scholar
• National Drug Formulary. (2004).
   Google Scholar
• Ponce J, Arguello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig. Dis. Sci.49(6), 931–936 (2004).
   PubMed Web of Science ®Google Scholar
• Bytzer P, Blum A, De Herdt D, Dubois D, The Trial Investigators. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Ali. Pharmacol. Ther.20(2), 181–188 (2004).
   PubMed Web of Science ®Google Scholar
• Kao AW, Sheu BS, Sheu MJ et al. On-demand therapy for Los Angeles grade A and B reflux esophagitis: esomeprazole versus omeprazole. J. Formos. Med. Assoc.102(9), 607–612 (2003).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Venables TL, Green JR et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negativegastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur. J. Gastroenterol. Hepatol.14(8), 857–863 (2002).
   PubMed Web of Science ®Google Scholar
• Johnsson F, Moum B, Vilien M, Grove O, Simren M, Thoring M. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand. J. Gastroenterol.37(6), 642–647 (2002).
   PubMed Web of Science ®Google Scholar
• Wahlqvist P, Junghard O, Higgins A, Green J. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. PharmacoEconomics20(4), 267–277 (2002).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Ali. Pharmacol. Ther.15(3), 347–354 (2001).
   PubMed Web of Science ®Google Scholar
• Faaij RA, Van Gerven JM, Jolivet-Landreau I et al. Onset of action during on-demand treatment with maalox suspension or low-dose ranitidine for heartburn. Ali. Pharmacol. Ther.13(12), 1605–1610 (1999).
   PubMed Web of Science ®Google Scholar
• Wilhelmsen I, Hatlebakk JG, Olafsson S, Berstad A. On demand therapy of reflux oesophagitis – a prospective study of symptoms, patient satisfaction and quality of life. Ali. Pharmacol. Ther.13(8), 1035–1040 (1999).
   PubMed Web of Science ®Google Scholar
• Lind T, Havelund T, Lundell L et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis – a placebo-controlled randomized trial. Ali. Pharmacol. Ther.13(7), 907–914 (1999).
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Shi G, Simon B, Casset-Semanza F, Slama A. On-demand treatment of gastro-oesophageal reflux symptoms: a comparison of ranitidine 75 mg with cimetidine 200 mg or placebo. Ali. Pharmacol. Ther.12(9), 909–917 (1998).
   PubMed Web of Science ®Google Scholar
• Johannessen T, Kristensen P. On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tablets. Clin. Ther.19(1), 73–81 (1997).
   PubMed Web of Science ®Google Scholar